Christopher J. Senner Sells 100,000 Shares of Exelixis, Inc. (EXEL) Stock
Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher J. Senner sold 100,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $26.79, for a total transaction of $2,679,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Exelixis, Inc. (NASDAQ EXEL) traded up 0.44% during trading on Thursday, hitting $27.23. 4,039,806 shares of the company traded hands. The company’s 50-day moving average is $27.05 and its 200 day moving average is $23.36. The firm has a market cap of $8.00 billion, a price-to-earnings ratio of 137.53 and a beta of 1.97. Exelixis, Inc. has a 52-week low of $10.04 and a 52-week high of $29.50.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The firm had revenue of $99.01 million for the quarter, compared to analyst estimates of $85.27 million. During the same period last year, the firm posted ($0.15) EPS. Exelixis’s quarterly revenue was up 173.1% on a year-over-year basis. On average, equities analysts anticipate that Exelixis, Inc. will post $0.26 earnings per share for the current year.
Large investors have recently bought and sold shares of the stock. First Quadrant L P CA purchased a new position in Exelixis in the 2nd quarter valued at $144,000. Meeder Asset Management Inc. purchased a new position in Exelixis in the 1st quarter valued at $170,000. Atlantic Trust Group LLC purchased a new position in Exelixis in the 1st quarter valued at $216,000. Wetherby Asset Management Inc. purchased a new position in Exelixis in the 2nd quarter valued at $218,000. Finally, Caxton Associates LP purchased a new position in Exelixis in the 2nd quarter valued at $227,000. Hedge funds and other institutional investors own 79.20% of the company’s stock.
Several research firms have recently commented on EXEL. Royal Bank Of Canada began coverage on shares of Exelixis in a report on Thursday. They issued an “outperform” rating on the stock. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Exelixis in a report on Monday, June 5th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $26.00 price objective on shares of Exelixis in a report on Thursday, August 3rd. Piper Jaffray Companies reiterated a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research note on Thursday, August 3rd. Finally, William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Friday, June 16th. Five analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. Exelixis currently has a consensus rating of “Buy” and a consensus target price of $25.82.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.